Investing

How to Explain a Complex Product to Investors Who Don't Know Your Industry

How to Explain a Complex Product to Investors Who Don't Know Your Industry

Investors who don't know your industry can't evaluate your technology — so they evaluate you. Lead with the outcome, not the mechanism. Build your "dinner party sentence" before you build the deck. Use depth as a reward for investors who lean in, not as your opening move.

  • Start with the job your product does, not how it does it

  • Reframe every technical claim as an investor risk question

  • Reserve technical depth for the appendix — and own it when they ask

Your Investor Has About Two Minutes

I've sat across from enough founders to know when a pitch is already lost before it starts. Not because the product is bad — often it's extraordinary — but because the room is full before they've even opened the deck.

DocSend's 2026 benchmarks put average investor review time at around two minutes and twenty-four seconds. Storydoc's dataset of over a million viewing sessions found that only 32% of investors finish a ten-slide deck. But if someone makes it past slide three, 82% go all the way. Slide three is the cliff.

For a complex product, that cliff is steeper. You don't have the luxury of ten minutes to build to your insight. You need to earn the next slide every time.

The Mechanism Is Not the Message

Here's what I keep seeing with technical founders. They know their product better than anyone in the room. Deeply, rigorously, correctly. And that expertise becomes the thing that gets in the way.

A founder that turned to us at Whitepage made a comment that stuck with me. She'd been pitching for months. "When people ask what we do," she said, "you always take a deep breath — because it gets complicated real fast." She had spent years building the science, and thirty seconds into explaining it, she was already losing the room.

The problem wasn't the technology. She was just answering the wrong question. Investors who don't know your field aren't asking how it works. They're asking: who pays for this, why now, and what could go wrong? Those are risk questions dressed as curiosity questions.

Find Your Dinner Party Sentence First

Before you touch the deck, do this: explain your company to someone who has nothing to do with your industry. Not an advisor or potential investor. Someone who will look at you blankly if you say "bioinformatics platform" or "infrastructure-layer API."

That founder eventually landed on: "We take compounds from agricultural waste and convert them into natural chemicals for crop protection." One sentence. No jargon. A complete thought that travels. That sentence became the spine of her entire deck.

Your dinner party sentence isn't the dumbed-down version of your pitch. It's the clearest version. There's a real difference. ESCP Business School research, across 547 startup pitches, found that investors don't reward oversimplification. They reward founders who can handle complexity and still communicate with discipline. The signal isn't that your product is simple. The signal is that you are.

Reframe Every Slide as a Risk Question

Once you have your sentence, take it to the deck and apply one filter to every slide: what risk question is this investor actually asking?

A supply chain slide isn't about logistics. It's about whether the business can scale without breaking. A regulatory pathway slide isn't about compliance timelines. It's about time-to-revenue and defensibility. A platform architecture slide isn't about the stack. It's about whether you can build this faster than a well-funded competitor who decides to copy you.

Most investors evaluating a technical pitch outside their domain aren't asking themselves "do I understand this?" They're scanning for: traction, clarity, market potential, team credibility. That's the signal set they default to when they can't assess the technology directly. Build your slides for those signals. Let the technical content serve as evidence, not explanation.

Your Appendix Is a Confidence Signal, Not an Overflow Bin

The instinct with a complex product is to put everything in the main deck. Answer every question before it's asked. Prove you've thought of everything. Resist this.

What works, and we've seen it across technical clients from biotech to AI infrastructure, is a lean main narrative paired with a well-built appendix. When an investor asks a hard technical question and you pull up a precise slide in response, something shifts in the room. It shows you anticipated the concern. That you know what a serious investor worries about. That the depth is there — you just chose not to lead with it.

One team kept their main deck to fourteen slides. The appendix covered regulatory pathways, supply security analysis, competitive moat detail. They rarely got through it in a meeting. They didn't need to. The fact that it existed did the work.

You're Not Choosing Between Simple and Deep

The real move here, and it took years of working through this with technical founders to land on it cleanly, is that you're not choosing between simplicity and depth. You're choosing the order.

Start simple enough that any investor can decide, in three slides, whether this is worth the next hour of their attention. Then earn the right to go deeper with the ones who lean in. That structure isn't condescending to your technology. It's respectful of your audience.

The approach starts well before the design. It starts with the narrative — figuring out what the story needs to do before you figure out how it looks. It's the part of every project at Whitepage that takes the longest, and the part clients most often underestimate going in.

The deck is the easy part. The sentence is the work.

Tanya Slyvkin is the founder of Whitepage Studio, a presentation design agency that has helped clients raise over $1.7B across 4,000+ projects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Top 10 Most Recent News Articles

Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 93

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 208

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading
Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Updated Category News Views 40

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Continue Reading
Lunit, Summit Tackle Tumor Analysis with AI Platform

Updated Category News Views 212

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...

Continue Reading
DigitalXForce Booms with 514% Growth and Major Backing

Updated Category News Views 228

Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 81

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 34

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 121

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 74

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 150

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Fluor Corporation's Recent Class Action Developments

Updated Category News Views 255

Fluor Corporation: An Overview of Recent Developments Fluor Corporation is a global leader in providing engineering, procurement, and construction (EPC) services, along with project management support. The company is dedicated to delivering essential infrastructure and the latest technology solutions while enhancing its operational efficiencies. Class Period and...

Continue Reading
Securing Your Rights: A Call to Sarepta Therapeutics Investors

Updated Category News Views 150

Urgent Reminder for Sarepta Therapeutics Investors In light of recent legal developments, it's crucial for investors of Sarepta Therapeutics, Inc. to take action regarding their investments in this biopharmaceutical company. Investors who acquired securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) are being notified of upcoming legal deadlines that could impact their...

Continue Reading
GMT Pay Revolutionizes Everyday Spending with Web3 Earnings

Updated Category News Views 151

GMT Pay: A New Era in Payment Solutions Welcome to the exciting world of GMT Pay, the groundbreaking payment solution that allows users to turn their Web3 earnings into everyday purchases. This innovative platform is spearheaded by FSL, the development studio behind the renowned Web3 lifestyle app, STEPN. With GMT Pay, users can easily access their earnings from various...

Continue Reading
Trucept, Inc. Unveils 2022 Financial Results and Future Prospects

Updated Category News Views 40

Trucept, Inc. Announces Major Financial Developments Trucept Inc. DBA Afinida is excited to share its audited financial results for the year 2022. With a keen focus on delivering transparency, the company underscores its commitment to its shareholders and clients alike. CEO Norman Tipton expresses optimism about the upcoming 2023 financial report, which is expected to be...

Continue Reading
Bitcoin's Critical Support Level for Future Growth Explained

Updated Category News Views 174

Understanding Bitcoin's Correction Phase Bitcoin's (CRYPTO: BTC) ongoing correction phase has garnered much attention among traders and investors alike. Key Insights From Technical Analysis Technical analyst Kevin has pointed out that Bitcoin's correction patterns notably exhibit similarities across different market cycles. Historically, even amidst various macroeconomic...

Continue Reading